BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 25168939)

  • 21. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 23. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
    Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
    Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hemorrhage with the target-specific oral anticoagulants.
    Pluym M; Howell G
    Hosp Pract (1995); 2014 Aug; 42(3):75-83. PubMed ID: 25255409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
    Prandoni P; Temraz S; Taher A
    Semin Hematol; 2014 Apr; 51(2):121-30. PubMed ID: 24861796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 32. Are new oral anticoagulant dosing recommendations optimal for all patients?
    Powell JR
    JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 34. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
    J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
    [No Abstract]   [Full Text] [Related]  

  • 35. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advantages and limitations of the new anticoagulants.
    Schulman S
    J Intern Med; 2014 Jan; 275(1):1-11. PubMed ID: 24112453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 39. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quick reference guide to apixaban.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.